Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission—confounded by the gut microbiome?

Leong Rupert W. L.; Kaakoush Nadeem O.; Yau Yunki Y.; Wasinger Valerie C.

首页> 外文期刊>Alimentary pharmacology & therapeutics. >Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission—confounded by the gut microbiome?

【24h】

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission—confounded by the gut microbiome?

机译：社论：用于结直肠腺癌的代谢物生物标志物和肠道缓解肠综合征和溃疡性结肠炎之间的差异肠道肠道肠道 - 肠道微生物组合

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Alimentary pharmacology & therapeutics.》 |2019年第8期|共2页
作者
Leong Rupert W. L.; Kaakoush Nadeem O.; Yau Yunki Y.; Wasinger Valerie C.;
展开▼
作者单位

Faculty of MedicineSouth Western Clinical School UNSWSydney Australia;

School of Medical SciencesUNSWSydney Australia;

Gastroenterology and Liver ServicesConcord Repatriation General HospitalSydney Australia;

Bioanalytical Mass Spectrometry FacilityUNSWSydney Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission—confounded by the gut microbiome? [J] . Leong Rupert W. L., Kaakoush Nadeem O., Yau Yunki Y., Alimentary pharmacology & therapeutics. . 2019,第8期

机译：社论：用于结直肠腺癌的代谢物生物标志物和肠道缓解肠综合征和溃疡性结肠炎之间的差异肠道肠道肠道 - 肠道微生物组合
2. Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission — confounded by the gut microbiome? Authors' reply [J] . Bond Ashley, Probert Chris Alimentary pharmacology & therapeutics. . 2019,第8期

机译：社论：结直肠腺癌的代谢物生物标志物和临床缓解中肠辨率综合征和溃疡性结肠炎之间的分化 - 由肠道微生物组混淆？作者的回复
3. Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission – confounded by the gut microbiome? Authors’ reply [J] . Keshteli Ammar Hassanzadeh, Madsen Karen L., Mandal Rupasri, Alimentary pharmacology & therapeutics. . 2019,第8期

机译：社论：结直肠腺癌的代谢物生物标志物和临床缓解中肠辨率综合征和溃疡性结肠炎之间的分化 - 由肠道微生物组混淆？作者的回复
4. Irritable bowel syndrome: newer pharmacological agents acting on the gut [C] . Michael Camilleri World Congress on Psychosomatic Medicine . 2002

机译：肠易激综合征：新药理学剂作用于肠道
5. Lactobacillus reuteri reduces visceral hypersensitivity and alters gut motility without changing gut serotonin availability in an animal model of the irritable bowel syndrome. [D] . Jakupovic, Jasmina. 2013

机译：在肠易激综合征的动物模型中，路氏乳杆菌可降低内脏超敏反应并改变肠蠕动，而不会改变肠内5-羟色胺的利用率。
6. Randomised Clinical Trial: Gut Microbiome Biomarkers are Associated with Clinical Response to a Low FODMAP Diet in Children with Irritable Bowel Syndrome [O] . Bruno P. Chumpitazi, Julia L. Cope, Emily B. Hollister, -1

机译：随机临床试验：肠道微生物组生物标志物与肠易激综合征患儿对低FODMAP饮食的临床反应相关
7. Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply [O] . Ashley Bond, Chris Probert 2019

机译：社论：结直肠腺癌的代谢物生物标志物和临床缓解肠综合征和溃疡性结肠炎之间的差异化 - 肠道微生物组织混淆？作者的回复

Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission—confounded by the gut microbiome?

著录项

相似文献

相关主题

期刊订阅